Lessons Learned through Research: Do Hospitals and Ambulatory Centers Follow Guideline Recommended Care Nancy Albert, PhD, RN, CCNS, CCRN, NE-BC, FAHA, FCCM Senior Director Nursing Research and Innovation; CNS, Kaufman Center for Heart Failure May 2012
46
Embed
Lessons Learned through Research: Do Hospitals and Ambulatory Centers Follow Guideline Recommended Care Nancy Albert, PhD, RN, CCNS, CCRN, NE-BC, FAHA,
This document is posted to help you gain knowledge. Please leave a comment to let me know what you think about it! Share it to your friends and learn new things together.
Transcript
Lessons Learned through Research: Do Hospitals and Ambulatory Centers Follow Guideline Recommended
Senior Director Nursing Research and Innovation;CNS, Kaufman Center for Heart Failure
May 2012
2
Presenter Disclosure InformationNancy M. Albert PhD, CCNS, CHFN, CCEN, FAHA, FCCMLessons Learned through Research: Do Hospitals and AmbulatoryCenters Follow Guideline Recommended Care
GWTG-HF: Warfarin at Hospital Discharge Among Pts Admitted for HF w Atrial Fib
Piccini JP et al. JACC 2009;54:1280-1289
CHADS2 score: CHF, HTN, age > 75, DM, prior stroke/TIA
War
fari
n D
isch
arg
e (%
)
01
20
40
60
80
100
2 3 4 5 6Chads2 Score
70.966.5 63.6 64.3 65.8
59.5
P<.0001 for trend
Are hospitals delivering
optimal evidence-based
recommendations?
Hernandez, A. F. et al. JAMA 2007;298:1525-1532.
GWTG-HF: Race and Gender Disparities in ICD Use at Discharge Among Eligible Patients With HF
Black female
White female
Black male
0 0.4 0.80.2 0.6 1.0
43.633.4 29.8 28.2
0102030405060708090
100
White Male
Black Male
WhiteFemale
BlackFemale
N= 13,034 pts
GWTG-HF: Hospital Variation and Characteristics of ICD Use
• January 2005 – June 2007
• New or Discharge prescription for ICD Tx in patients with EF ≤ 30% without documented contraindication
–54,750 pts from 234 hospitals
–Of 12,693 pts, 2545 had prior ICD (20% use)
–Of 10,148 (134 hospitals):
–Overall Use/Planned implementation = 20%
Shah B, et al. JACC 2009;53:416-22.
Hospital Variation in ICD Use
Patient Factors
High Use
N=48
Med. Use
N=42
Low Use
N=44
P Value
Female 34% 38% 36% <0.03
Race-AA 22% 33% 32% <0.001
High Chol 38% 32% 30% <0.001
Hx MI 15% 9% 11% <0.001
Hx HTN 63% 66% 64% 0.004
Shah B, et al. JACC 2009;53:416-22.
Are disparities in care present
by patient features?
New or Planned ICD Use-GWTG-HF
Shah B, et al. JACC 2009;53:416-22.
GWTG - HF Hospital Site
1 11 21 31 41 51 61 71 81 91 101 111 121 131
Ho
spit
al I
CD
rat
e (%
)
0
20
40
60
80
100
Hospital ICD Use Associations with Hospital Characteristics
Shah B, et al. JACC 2009;53:416-22.
Aca
dem
ic
Adj
uste
d IC
D r
ate
(%)
0
20
40
60
80
100N
on-a
cade
mic
Hea
rt tra
nspl
ants
No
hear
t tra
nspl
ants
PC
I cap
able
No
PC
IC
AB
G c
apab
leN
o C
AB
GN
orth
east
Mid
wes
tS
outh
Wes
tB
eds
<100
Bed
s 10
0-19
9B
eds
200-
299
Bed
s 30
0-39
9B
eds
400-
499
>50
0 B
eds
Are disparities in care present
by hospital features?
Median, 49.1Mean, 50.7
IMPROVE-HF: Variation in OPD HF Care
Fonarow GC, et al. Circ Heart Fail. 2008;1:98–106.
ADHERE-HF: Rates of Conformity by Practice Setting and Differences in Hospital Level Outcomes; > 80,000 Hosp. Admissions
Fonarow GC, et al. Arch Intern Med 2005; 165:1469–1477
Median, 33.3Mean, 35.0
IMPROVE-HF: Variation in OPD HF Care
Fonarow GC, et al. Circ Heart Fail. 2008;1:98–106.
Median, 33.3Mean, 37.3
IMPROVE-HF: Variation in OPD HF Care
Fonarow GC, et al. Circ Heart Fail. 2008;1:98–106.
Median, 60.7Mean, 59.8
IMPROVE-HF: Variation in OPD HF Care
Fonarow GC, et al. Circ Heart Fail. 2008;1:98–106.
Are cardiologist practices
delivering optimal
evidence-based
recommendations?
IMPROVE-HF: Improvement in Quality Measures at 24 Months (Pt. Level Analysis)
80%
86%
34%
69%
38%
49%
62%
84%
93%
51%
69%
58%
71%69%
87%
94%
62%
69% 69%
79%
71%
0%
20%
40%
60%
80%
100%
Baseline 12 months 24 months
ACEI/ARB ß-blocker Aldosterone Antagonist
Anticoagulant for AF
CRT ICD HF Education
*
*
*
*
*
**
*
*
*
**
Eli
gib
le P
atie
nts
Tre
ate
dE
lig
ible
Pat
ien
ts T
rea
ted
Fonarow GC, et al. Circulation. 2010;122:585-96.
P-values are for relative change; *, P <0.001 vs. baselineBaseline N= 15,177; 24 Mo. N= 11,621; 167 practices
IMPROVE-HF: Baseline Measure Conformity: Alive vs. Dead at 24-Months
The baseline process measure conformity was significantly lower among patients who died compared with those who survived for 5 of 7 individual measures.
The baseline process measure conformity was significantly lower among patients who died compared with those who survived for 5 of 7 individual measures.
Fonarow GC, et al. Circulation. 2011;123(15):1601-1610.
IMPROVE-HF Nested Case-Control Analysis: Baseline Use of Guideline Recommended Therapies in Cases (N=1376; Dead) and Controls (N= 2752; Alive) at 24-months (matched at 1:2 ratio)
0%
10%
20%
30%
40%
50%
60%
70%
80%
90%
100%
ACEi/ARB
B-Block
ers
Aldo. Antag
onist
Anticoag fo
r AF
ICD/CRT-D
CRT-P/C
RT-D
HF Educa
tion
CasesControls
P<0.0001
P=0.4046
P=0.0094
P<0.0001
P=0.0019
P<0.0001
P<0.0001
Fonarow GC, et al. J Am Heart Assoc 2012;1:16-26.
IMPROVE-HF Nested Case-Control Analysis: Mortality Reduction Based on Number of Guideline-Recommended Therapies at Baseline
24 Month MortalityAdjusted Odds Ratios (95% CI)
24 Month MortalityAdjusted Odds Ratios (95% CI)
Number of Therapies (vs. 0 or 1 therapy)
2 therapies
3 therapies
4 therapies
5, 6, or 7 therapies
Odds Ratio(95% confidence interval)
0.63 (0.47-0.85)(P =0.0026)
0.38 (0.29-0.51)(P <0.0001)
0.30 (0.23-0.41)(P <0.0001)
0.31 (0.23-0.42)(P <0.0001)
0 0.5 1 1.5 2
Fonarow GC, et al. J Am Heart Assoc 2012;1:16-26.
IMPROVE-HF: Incremental Benefits with HF Therapies(Cumulative % Reduction in Odds of Death at 24 Months)
-39%
-63%
-76%-81% -83% -81%
-100%
-90%
-80%
-70%
-60%
-50%
-40%
-30%
-20%
-10%
0%Beta Blocker
Beta Blocker +ACEI/ARB
Beta Blocker +ACEI/ARB + ICD
Beta Blocker +ACEI/ARB + ICD + HF
Education
Beta Blocker +ACEI/ARB + ICD + HF
Education +anticoagulants for AF
Beta Blocker +ACEIARB + ICD + HF
Education +Anticoagulant for AF
+ CRT
-28% to -49%P<0.0001
-54% to -71%P<0.0001
-68% to -81%P<0.0001
-75% to -86%P<0.0001
-77% to -88%P<0.0001
-72% to -87%P<0.0001
Fonarow GC, et al. J Am Heart Assoc 2012;1:16-26.
IMPROVE-HF: Incremental Benefit with HF Therapies(Cumulative % Reduction in Odds of Death at 24 Months Associated with Sequential Treatments)